Antengene and MSD Announce Global Clinical Collaboration on Immunotherapy Combo Trial
May 21, 2025 | 07:00
The study will evaluate ATG-022 in combination with KEYTRUDA®, targeting gastrointestinal cancers.
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024
November 06, 2024 | 07:30
Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer.
Mobile Version